Ibandronic acid - Roche
Alternative Names: BM 210955; Bondronat; Boniva; Bonviva; CT-064; Ibandronate; Ibandronate sodium hydrate; Methylpentylaminopropylidene; R 484; RG484; RO 2005450; Ro200-5450; Ro200-5450iv; Ro200-5450po; RPR 102289ALatest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Roche
- Developer Chugai Pharmaceutical; Roche; Taisho Pharmaceutical
- Class Antihypercalcaemics; Bisphosphonates; Calcium regulators; Osteoporosis therapies; Small molecules
- Mechanism of Action Bone resorption factor inhibitors; Dimethylallyltranstransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cancer metastases; Malignant hypercalcaemia; Osteoporosis; Postmenopausal osteoporosis
- Discontinued Cancer pain
Most Recent Events
- 24 Nov 2022 Taisho Pharmaceutical acquires Ibandronic acid (Bonviva®) from Roche and Chugai Pharmaceutical
- 06 Sep 2022 No development reported - Phase-III for Postmenopausal osteoporosis (In the elderly, In adults) in Denmark, Spain, Italy, Germany, Czech Republic, Hungary, United Kingdom (IV) (NDR Batch 23)
- 16 Sep 2016 Updated efficacy data from a phase III MOVEST trial in Oesteoporosis presented at the 38th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR-2016)